Gemcitabine and the monoclonal antibody nimotuzumab versus gemcitabine and placebo for the treatment of chemotherapy-naive patients (pts) with advanced pancreatic cancer (PC): A multicentre, randomized phase IIb/IIIa study

被引：0
|
作者：
Strumberg, D. [1 ]
Schultheis, B. [1 ]
Ebert, M. P. [2 ]
Siveke, J. [2 ]
Kerkhoff, A. [3 ]
Berdel, W. [3 ]
Hofheinz, R. [4 ]
Behringer, D. M. [5 ]
Schmidt, W. E. [6 ]
Goker, E. [7 ]
De Dosso, S. [8 ]
Kneba, M. [9 ]
Yalcin, S. [10 ]
Overkamp, F.
Schlegel, F. [11 ]
Dommach, M. [12 ]
Rohrberg, R. [13 ]
Steinmetz, T. [14 ]
Reuter, D. [15 ]
Bach, F. [15 ]
机构：
[1] Marienhosp Herne, Herne, Germany
[2] Tech Univ Munich, Klinikum Rechts Isar, Munich, Germany
[3] Univ Hosp Munster, Munster, Germany
[4] Univ Med Ctr Mannheim, Dept Hematol & Med Oncol, Mannheim, Germany
[5] Augusta Kranken Anstalt, Bochum, Germany
[6] Ruhr Univ Bochum, St Josef Hosp, Med Klin 1, Bochum, Germany
[7] Ege Univ, Sch Med, Izmir, Germany
[8] Oncol Inst Southern Switzerland, Bellinzona, Switzerland
[9] Univ Med Ctr Schleswig Holstein, Dept Med, Kiel, Germany
[10] Hacettepe Univ Hosp, Ankara, Turkey
[11] St Antonius Hosp, Eschweiler, Germany
[12] Sana Kliniken, Med Versorgungszentrum Onkol, Dusseldorf, Germany
[13] Tagesklin Haematol Onkol & Gastroenterol, Halle, Germany
[14] Grp Practice Hematol Oncol Cologne, Cologne, Germany
[15] Oncosci AG, Wedel, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：57 / 57
页数：1
相关论文
共 50 条
  • [1] Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC)
    Strumberg, Dirk
    Schultheis, Beate
    Ebert, Matthias Philip
    Kerkhoff, A.
    Hofheinz, Ralf Dieter
    Behringer, Dirk M.
    Schmidt, Wolfgang E.
    Goker, Erdem
    De Dosso, Sara
    Kneba, Michael
    Yalcin, Suayib
    Overkamp, Friedrich
    Schlegel, Frank
    Dommach, M.
    Rohrberg, Robert
    Steinmetz, Tilman
    Reuter, Dirk
    Bach, Ferdinand
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naive Pancreatic Adenocarcinoma
    Cohen, Steven J.
    Zalupski, Mark M.
    Conkling, Paul
    Nugent, Francis
    Ma, Wen Wee
    Modiano, Manuel
    Pascual, Rolan
    Lee, Fa Chyi
    Wong, Lucas
    Hersh, Evan
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (03): : 230 - 235
  • [3] Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study
    Schultheis, B.
    Reuter, D.
    Ebert, M. P.
    Siveke, J.
    Kerkhoff, A.
    Berdel, W. E.
    Hofheinz, R.
    Behringer, D. M.
    Schmidt, W. E.
    Goker, E.
    De Dosso, S.
    Kneba, M.
    Yalcin, S.
    Overkamp, F.
    Schlegel, F.
    Dommach, M.
    Rohrberg, R.
    Steinmetz, T.
    Bulitta, M.
    Strumberg, D.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (10) : 2429 - 2435
  • [4] Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naive patients with advanced pancreatic cancer (APC)
    Cheverton, P
    Friess, H
    Andras, C
    Salek, T
    Geddes, C
    Bodoky, G
    Valle, J
    Humblet, Y
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 314S - 314S
  • [5] Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
    Cunningham, David
    Chau, Ian
    Stocken, Deborah D.
    Valle, Juan W.
    Smith, David
    Steward, William
    Harper, Peter G.
    Dunn, Janet
    Tudur-Smith, Catrin
    West, Julia
    Falk, Stephen
    Crellin, Adrian
    Adab, Fawzi
    Thompson, Joyce
    Leonard, Pauline
    Ostrowski, Joe
    Eatock, Martin
    Scheithauer, Werner
    Herrmann, Richard
    Neoptolemos, John P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) : 5513 - 5518
  • [6] Phase II trial of gemcitabine, carboplatin, and bevacizumab in chemotherapy-naive patients (Pts) with advanced/metastatic urothelial carcinoma (UC)
    Balar, A. V.
    Milowsky, M. I.
    Apolo, A. B.
    Ostrovnaya, I.
    Iasonos, A.
    Trout, A.
    Regazzi, A. M.
    Garcia-Grossman, I. R.
    Gallagher, D. J.
    Bajorin, D. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [7] A randomized phase III study of irinotecan/gemcitabine combination versus gemcitabine in patients with advanced/metastatic pancreatic cancer.
    Stathopoulos, GP
    Aravantinos, G
    Syrigos, K
    Kalbakis, K
    Karvounis, N
    Papakotoulas, P
    Boukovinas, J
    Potamianou, A
    Polyzos, A
    Christophilakis, CH
    Georgoulias, V
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 334S - 334S
  • [8] Docetaxel (Do) and gemcitabine (Gem) in advanced pancreatic cancer (APC) patients (pts): A multicentre study
    Des Guetz, G.
    Chauvenet, L.
    Paraiso, D.
    Mayeur, D.
    Aparicio, T.
    Chirat, E.
    Boiron, C.
    Bouleuc-Parrot, C.
    Pujade-Lauraine, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
    Ueno, Hideki
    Ikeda, Masafumi
    Ueno, Makoto
    Mizuno, Nobumasa
    Ioka, Tatsuya
    Omuro, Yasushi
    Nakajima, Takako Eguchi
    Furuse, Junji
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (03) : 595 - 603
  • [10] Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
    Hideki Ueno
    Masafumi Ikeda
    Makoto Ueno
    Nobumasa Mizuno
    Tatsuya Ioka
    Yasushi Omuro
    Takako Eguchi Nakajima
    Junji Furuse
    [J]. Cancer Chemotherapy and Pharmacology, 2016, 77 : 595 - 603
12345